Osteoarthritis
Diclofenac sodium, as a single ingredient or in combination with misoprostol, has been shown to be effective in the management of the signs and symptoms of osteoarthritis.
Rheumatoid Arthritis
Diclofenac sodium, as a single ingredient or in combination with misoprostol, has been shown to be effective in the management of the signs and symptoms of rheumatoid arthritis.
Upper Gastrointestinal Safety
Diclofenac, and other NSAIDs, have caused serious gastrointestinal toxicity, such as bleeding, ulceration, and perforation of the stomach, small intestine or large intestine. Misoprostol has been shown to reduce the incidence of endoscopically diagnosed NSAID-induced gastric and duodenal ulcers. In a 12-week, randomized, double-blind, dose-response study, misoprostol 200 mcg administered four, three or two times a day, was significantly more effective than placebo in reducing the incidence of gastric ulcer in osteoarthritis and rheumatoid arthritis patients using a variety of NSAIDs. The three times a day regimen was therapeutically equivalent to misoprostol 200 mcg four times a day with respect to the prevention of gastric ulcers. Misoprostol 200 mcg given two times a day was less effective than 200 mcg given three or four times a day. The incidence of NSAID-induced duodenal ulcer was also significantly reduced with all three regimens of misoprostol compared to placebo (see Table 3).
| Misoprostol 200 mcg Dosage Regimen | ||||
|---|---|---|---|---|
| Placebo | two times a day | three times a day | four times a day | |
| N=1623; 12 weeks | ||||
| ||||
Gastric ulcer | 11% | 6%* | 3%* | 3%* |
Duodenal ulcer | 6% | 2%* | 3%* | 1%* |
Results of a study in 572 patients with osteoarthritis demonstrate that patients receiving ARTHROTEC have a lower incidence of endoscopically defined gastric ulcers compared to patients receiving diclofenac sodium (see Table 4).
| Osteoarthritis patients with history of ulcer or erosive disease (N=572), 6 weeks | Incidence of ulcers | |
|---|---|---|
| Gastric | Duodenal | |
| ||
ARTHROTEC 50 three times a day | 3%* | 6% |
ARTHROTEC 75 two times a day | 4%* | 3% |
Diclofenac sodium 75 mg two times a day | 11% | 7% |
Placebo | 3% | 1% |
Osteoarthritis
Diclofenac sodium, as a single ingredient or in combination with misoprostol, has been shown to be effective in the management of the signs and symptoms of osteoarthritis.
Rheumatoid Arthritis
Diclofenac sodium, as a single ingredient or in combination with misoprostol, has been shown to be effective in the management of the signs and symptoms of rheumatoid arthritis.
Upper Gastrointestinal Safety
Diclofenac, and other NSAIDs, have caused serious gastrointestinal toxicity, such as bleeding, ulceration, and perforation of the stomach, small intestine or large intestine. Misoprostol has been shown to reduce the incidence of endoscopically diagnosed NSAID-induced gastric and duodenal ulcers. In a 12-week, randomized, double-blind, dose-response study, misoprostol 200 mcg administered four, three or two times a day, was significantly more effective than placebo in reducing the incidence of gastric ulcer in osteoarthritis and rheumatoid arthritis patients using a variety of NSAIDs. The three times a day regimen was therapeutically equivalent to misoprostol 200 mcg four times a day with respect to the prevention of gastric ulcers. Misoprostol 200 mcg given two times a day was less effective than 200 mcg given three or four times a day. The incidence of NSAID-induced duodenal ulcer was also significantly reduced with all three regimens of misoprostol compared to placebo (see Table 3).
| Misoprostol 200 mcg Dosage Regimen | ||||
|---|---|---|---|---|
| Placebo | two times a day | three times a day | four times a day | |
| N=1623; 12 weeks | ||||
| ||||
Gastric ulcer | 11% | 6%* | 3%* | 3%* |
Duodenal ulcer | 6% | 2%* | 3%* | 1%* |
Results of a study in 572 patients with osteoarthritis demonstrate that patients receiving ARTHROTEC have a lower incidence of endoscopically defined gastric ulcers compared to patients receiving diclofenac sodium (see Table 4).
| Osteoarthritis patients with history of ulcer or erosive disease (N=572), 6 weeks | Incidence of ulcers | |
|---|---|---|
| Gastric | Duodenal | |
| ||
ARTHROTEC 50 three times a day | 3%* | 6% |
ARTHROTEC 75 two times a day | 4%* | 3% |
Diclofenac sodium 75 mg two times a day | 11% | 7% |
Placebo | 3% | 1% |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.